1. The sharing of the GBM clinical trial result of ADCTA, Autologous Dendritic Cell / Tumor Antigen
2. The introduction of an immunotherapy, ADCTA for the incurable fatal malignant diseases
3. The introduction of an advanced facility of manufacturing ADCTA abide by PIC/S GMP
Safe Save Medical Cell Science & Technology Co., Ltd is a startup global company, established by Wen-Kuang Yang M.D., Ph.D, in2011, having a subsidiary Self Safe Save in TN, USA, since 2017. HQ locates in Taiwan, entered Hsinchu Biomedical Science Park where the advanced facility was built abide by PIC/S GMP regulatory in 2015.
Prof. Yang has spent 50 years in US and TW to invent the cancer immunotherapy ADCTA, Autologous Dendritic Cell/Tumor Antigen for incurable fatal malignant diseases, the accomplishment of the GBM, Glioblastoma Multiforme clinical trials of phase I and II, held by Prof. Yang began in 2002 and 2005, those results surpassed significantly the conventional cancer treatments by still alive presently 15 years 2 patient, 10 years 2 patients and 8 years 1 patient, and the median of life 29.47 months over 15 months and 5 years OS, overall survival 17.20% over 0.00%. In 2018, SSC embarks the GBM clinical trial phase III, a multiple medical centre project to collaborate with 7 medical centre level hospitals, 12 seasoned clinical doctors and118 volunteer patients expected in Taiwan. It programmes to carry through by 2021 and time to Taiwan market by 2022 to benefit TW NHI expense and every kind of solid tumor patients with a safe, efficacy and affordable immunotherapy while having a quality life still.
As regards, the latest regulatory deployed by TFDA in the early of Sept. 2018 to approve the immunotherapy for selected cancer patients, SSC has been working closely with numbers of hospital and is hoped to be the pioneer to serve the cancer immunotherapy in Taiwan. SSC exhorts to be the benchmark globally after serving numbers of patients with expected successful outcomes.
Cooperation projects and needs
SSC devotes to Research, Development, Manufacture, Sell and partnership :
1. Clinical Trial Collaboration
2. Immunocyte Banking Saved
3. Cancer Immunotherapy
4. R&D Out-Licensing Partnership
5. ADCTA Turnkey Out-Licensing Partnership
Prof. Yang worked at Oak-Ridge Graduate School of Biomedical Science, USA from 1968 to 1993, well noted for his works on reversing transcription of tRNA by detaching numbers of translation gene codes, discovering the reverse transcription tRNA primer of oncogenic virus, elucidating the mechanism of how host gene Fv-1 restricts leukemia virus, DNA transfection technology and retrotransposomes. Meanwhile, he served as US NIH experimental virology review committee and later US NCI cancer biology and immunology research plan consultative review committee.
In 1993, when he was invited by Taiwan ACADAIMA SINICA as a distinguished researcher at the Institute of Biomedical Sciences while he established NHRI, National Health Research Institute as well as the clinical cancer laboratory for the collaboration between Taipei Veterans General Hospital and National Taiwan University Hospital at the same period.
Began in 1996 he has devoted himself on Dendritic Cells cancer immunotherapy study, since then he has been the leading authority of GBM immunotherapy in Asia in view of the significant outcomes of 2 clinical trials he held.
Safe Save Medical Cell Sciences & Technology established in 2011 aimed to be able to fast expand ADCTA to other cancers than GBM and other regions than Taiwan.
To benefit the people in the world is the original intention of SSC, based on the prior positive results, which are GBM is treated as the most malignant disease due to the complication of human brain is, the dendritic cells are well recognized to be the best potent APC, antigen-presenting cell and non-specific effects and the knowhow of ADCTA we are very optimistic in the near future SSC product roadmap will fast expand GBM clinical trials in Taiwan domestic, US and global wide to (metastatic) lung cancer, colon cancer, pancreatic cancer, prostate cancer, (recurrence) ovarian cancer, breast cancer, etc.
ADCTA increase greatly the OS, overall survival of the incurable fatal malignant disease, improve the patients’ life quality meanwhile and its Know How distinguishes itself along from the conventional dendritic cell immunotherapy or traditional cancer treatments.
We warmly welcome and value every potential business or collaboration opportunity.
Sales & Marketing Division
Telephone: (03) 550-6696